Search company, investor...
Crown Bioscience company logo

Crown Bioscience

crownbio.com

Founded Year

2006

Stage

Acq - P2P | Acquired

Total Raised

$74.35M

Valuation

$0000 

About Crown Bioscience

Crown Bioscience is a drug discovery and development service company providing translational platforms and drug discovery solutions for its biotech and pharmaceutical partners in the dedicated therapeutic areas: oncology and metabolic disease. The company's HuPrime, HuKemia, HuBase, HuMark, HuTrial and HuSignature platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates.

Headquarters Location

16550 West Bernardo Drive Building 5, Suite 525

San Diego, California, 92127,

United States

+1 858 622 2900

Missing: Crown Bioscience's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Crown Bioscience's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Crown Bioscience

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Crown Bioscience is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Crown Bioscience Patents

Crown Bioscience has filed 7 patents.

The 3 most popular patent topics include:

  • Human proteins
  • Immunology
  • Bones of the head and neck
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/9/2021

2/22/2022

Clusters of differentiation, Immunology, Immune system, Olfactory receptors, Human proteins

Grant

Application Date

5/9/2021

Grant Date

2/22/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Olfactory receptors, Human proteins

Status

Grant

Latest Crown Bioscience News

Indivumed GmbH. (1/25/23). "Press Release: Crown Bioscience to Acquire Indivumeds Service Business and Supporting Biobank". San ...

Feb 2, 2023

Organisation Acquisition expands global service offering to include access and analysis of unique clinical biospecimens Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, has announced it has entered into an agreement to acquire the IndivuServ business unit of Indivumed GmbH. A Sales and Purchase Agreement (SPA) between both parties was executed on December 29, 2022, and subject to customary closing adjustments the transaction is expected to close in April 2023. Indivumed GmbH, founded in Germany in 2002, has an industry-leading and global reputation for the provision and analysis of clinical biospecimens. The transaction will generate two separate Indivumed entities, ‘Indivumed Therapeutics’ and ‘Indivumed Services’. The latter, which is the current IndivuServ business unit of the company, will become a wholly-owned subsidiary of Crown Bioscience and will incorporate all associated laboratory operations and staff located in Hamburg, Germany and Frederick, MD, USA. ‘Indivumed Therapeutics’, currently known as the IndivuType business unit will continue its groundbreaking work of translating high-quality biospecimens into multi-omics data and focus together with its international clinical partners on data- and AI-driven therapy development in oncology. Crown Bioscience’s proposed acquisition of ‘Indivumed Services’ includes both the expertly curated and characterized biobank comprising of almost one million samples with associated clinical data, and an extensive network of more than 60 clinical divisions in the US, Europe, and Asia. This network provides direct and controlled access to surgical biospecimens and blood samples annotated with comprehensive clinical data, all obtained in accordance with Indivumed’s unique SOPs to assure unrivaled quality, and thereby be suitable for multi-omics analyses and model development. The collection and associated network will also enable and support further expansion of Crown Bioscience’s biomarker development service offerings, as well as market-leading patient-derived xenograft (PDX), ex vivo patient tissue (EVPT), and in vitro tumor organoid platforms. ‘Indivumed Therapeutics’ will continue its global clinical cooperation with leading cancer clinics in Europe, Americas, and Asia and leverage its unique multi-omics database and advanced AI analytics to focus on identifying and validating novel targets and biomarkers to develop individualized cancer therapies. As part of the Agreement announced today, ‘Indivumed Therapeutics’ and Crown Bioscience with ‘Indivumed Services’ have additionally committed to a multi-year strategic partnership covering sample access and CRO service provision, while Hartmut Juhl, Founder and CEO of Indivumed Group, will join Crown Bioscience’s Scientific Advisory Board. Commenting on the Acquisition, Armin Spura, PhD, CEO of Crown Bioscience stated; “The acquisition of ‘Indivumed Services’ reflects Crown Bioscience’s commitment to expanding our translational research platforms to provide our customers with superior options for bridging the gap between preclinical and clinical research. Everyone at Crown Bioscience is delighted to be welcoming the talented staff of ‘Indivumed Services’ to the company, and excited about the long-term potential of our new relationship.” Prof. Dr. Hartmut Juhl, Founder and CEO of Indivumed Group, added “I am thrilled about the strategic partnership with Crown Bioscience, the first-in-class CRO. For 20 years Indivumed has driven the advancement of precision oncology by both its CRO services and its own R&D activities. Now, we can focus on our data analytics-driven drug and diagnostic development while we also benefit from the enhanced strength of Crown Bioscience’s R&D oncology offerings. With this partnership Crown Bioscience and Indivumed create a powerhouse for the advancement of precision oncology. Further, it fills me with great pride that my hometown Hamburg is emerging as a leading oncology biotech location.” About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases. We are the exclusive preclinical CRO to offer tumor organoid services with the well-established Hubrecht Organoid Technology. In addition, we have developed the largest commercially available PDX collection in the world. We focus on helping our customers develop novel therapies to maximize the chances that patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has 13 facilities across the United States, Europe, and Asia. For more information or to get in touch, please visit www.crownbio.com About Indivumed Driven by our mission to unveil the complex mechanisms of cancer and to advance precision oncology, Indivumed combines the world’s most comprehensive multi-omics data with extensive medical experience, bioinformatics expertise, and AI-integrated advanced analytics. Our global clinical network enables us to collect and analyze thousands of patient samples using a standardized approach to ensure biospecimen quality across our business areas. The unparalleled depth and quality of our data – coupled with our robust product and service offerings – gives us the ability to obtain novel insights and accelerate cancer research. For more information, visit www.indivumed.com. Media Inquiries:

Crown Bioscience Frequently Asked Questions (FAQ)

  • When was Crown Bioscience founded?

    Crown Bioscience was founded in 2006.

  • Where is Crown Bioscience's headquarters?

    Crown Bioscience's headquarters is located at 16550 West Bernardo Drive, San Diego.

  • What is Crown Bioscience's latest funding round?

    Crown Bioscience's latest funding round is Acq - P2P.

  • How much did Crown Bioscience raise?

    Crown Bioscience raised a total of $74.35M.

  • Who are the investors of Crown Bioscience?

    Investors of Crown Bioscience include JSR Corporation, Qiming Venture Partners, Lilly Asia Ventures, OrbiMed Advisors, CDIB Capital International and 13 more.

  • Who are Crown Bioscience's competitors?

    Competitors of Crown Bioscience include Strata Oncology, Ambrx, My Personal Therapeutics, Molecular Templates, AnaptysBio and 14 more.

Compare Crown Bioscience to Competitors

A
Ansata Therapeutics

Founded in early 2002 by Avalon Ventures and Domain Associates, Ansata Therapeutics is developing & commercializing novel medicines that capitalize on the Company's industry- leading expertise and intellectual property in molecular transduction. Ansata has several preclinical programs under development in the oncology and neurodegenerative disease areas. The company strives to rapidly advance lead compounds from late-stage preclinical research into clinical development by leveraging its proprietary knowledge of common dermatological diseases.

H
Harkness Pharmaceuticals

Harkness Pharmaceuticals is focused on developing anti-obesity therapeutics. Per the company, currently more than 20% of the U.S. population are considered clinically obese yet there remain few therapeutic option available. Harkness is performing exploratory human clinical trials in collaboration with the Pennington Institute in Louisiana.

VGXI Logo
VGXI

VGXI is a contract manufacturer of plasmid DNA. The company delivers flexibility, experience, reliability, and value to clients’ challenging programs. The company’s cGMP and non-cGMP products have passed rigorous international regulatory reviews.

I
InteKrin Therapeutics

InteKrin Therapeutics, Inc. is a privately-held clinical stage biopharmaceutical company based in Los Altos, California developing therapeutics for diabetes, obesity and metabolic disorders. The company was founded in 2005 by Denny Lanfear, a former Vice President and Officer of Amgen, and clinical endocrinologist Christos Mantzoros, M.D., DSc, FACP, FACE, Associate Professor of Medicine at Harvard Medical School. InteKrin's Scientific Advisory Board includes veterans from several successful biopharma organizations, internationally recognized experts in nuclear receptors and metabolism as well as top scientists formerly with the Food and Drug Administration. Its lead product, INT131, is a novel SPPARM (Selective Peroxisome Proliferator-Activated Receptor Modulator) which is in Phase II clinical trials for diabetes. The company focuses on high value therapeutics in addressing unmet medical needs. To learn more about InteKrin, visit www.intekrin.com

Q
Quintessence Biosciences

Quintessence Biosciences is a biopharmaceutical company focused on development of-based therapeutics as anti-cancer agents. The Company's products are based on the EVade Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.